Invasive Gastrointestinal Zygomycosis in a Liver Transplant Recipient: Case Report and Review of Zygomycosis in Solid-Organ Transplant Recipients

1995 ◽  
Vol 20 (3) ◽  
pp. 617-620 ◽  
Author(s):  
N. Singh ◽  
T. Gayowski ◽  
J. Singh ◽  
V. L. Yu
Keyword(s):  
Case Report ◽  
Transplant Recipient ◽  
Liver Transplant ◽  
Liver Transplant Recipient ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

scholarly journals FusariumInfection in a Kidney Transplant Recipient Successfully Treated with Voriconazole

2018 ◽  
Vol 2018 ◽  
pp. 1-4
Author(s):  
Ahmed M. Alkhunaizi ◽  
Ali M. Bazzi ◽  
Ali A. Rabaan ◽  
Elwaleed A. Ahmed
Keyword(s):  
Transplant Recipient ◽  
Kidney Transplant ◽  
High Mortality ◽  
Kidney Transplant Recipient ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

Fusariuminfections in solid-organ transplant recipients are rare and carry high mortality. We report a case of a kidney transplant recipient who developed infection withFusariumspecies. The patient received treatment with oral voriconazole for five months with good response.

Phaeohyphomycosis due toExophialainfections in solid organ transplant recipients: Case report and literature review

2017 ◽  
Vol 19 (4) ◽  
pp. e12723 ◽  
Author(s):  
Kate E. Oberlin ◽  
Anna J. Nichols ◽  
Rossana Rosa ◽  
Adriana Dejman ◽  
Adela Mattiazzi ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

Transmission of malaria from donors to solid organ transplant recipients: A case report and literature review.

2021 ◽  
Author(s):  
Fernando Rosso ◽  
Olga Lucia Agudelo Rojas ◽  
Cindy Carolina Suarez Gil ◽  
Jaime Alberto Lopez Vargas ◽  
Juan Esteban Gómez‐Mesa ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

scholarly journals A unique case of Miller Fisher-Guillain-Barré overlap syndrome in a liver transplant recipient

2021 ◽  
Author(s):  
Claudia Ramirez-Sanchez ◽  
Rehan Syed ◽  
Angela Meier ◽  
Jamie Nicole LaBuzetta ◽  
Diana J. Hylton ◽  
...  
Keyword(s):  
Liver Transplant ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Overlap Syndrome ◽  
Guillain Barre Syndrome ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients ◽  
Guillain Barré

AbstractGuillain-Barré syndrome (GBS) is an ascending demyelinating polyneuropathy often associated with recent infection. Miller Fisher syndrome represents a variant with predominant facial and cranial nerve involvement, although Miller Fisher and Guillain-Barré overlap syndromes can occur. Guillain-Barré spectrum syndromes have been thought to be rare among solid organ transplant recipients. We describe an immunocompromised patient with a liver transplant who presented with ophthalmoplegia and bulbar deficits. His symptoms rapidly progressed to a state of descending paralysis involving the diaphragm; he then developed acute respiratory failure and eventually developed quadriparesis. Electromyography and a nerve conduction study demonstrated a severe sensorimotor axonal polyneuropathy consistent with Miller Fisher variant Guillain-Barré syndrome. Despite several negative nasopharyngeal swabs for COVID-19 polymerase chain reaction, a serology for SARS-CoV-2 IgG was positive. He was diagnosed with Miller Fisher-Guillain-Barré overlap syndrome with rapid recovery following treatment with plasma exchange. Although Guillain-Barré is a rare complication in solid organ transplant recipients, this case highlights the importance of rapid diagnosis and treatment of neurologic complications in transplant patients. Furthermore, it demonstrates a possible case of neurological complications from COVID-19 infection.

scholarly journals An Atypical Subcutaneous Cytomegalovirus Infection Mimicking a Post-transplant Lymphoproliferative Disorder in a Solid Organ Transplant Recipient

2021 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Tae Young Park ◽  
Su Young Kim ◽  
Suk Hyun Bae ◽  
Sang Youb Han
Keyword(s):  
Transplant Recipient ◽  
Lymphoproliferative Disorder ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Cmv Infection ◽  
Organ Transplant Recipients ◽  
Post Transplant ◽  
Solid Organ Transplant Recipients

: Cytomegalovirus (CMV) infection is a common cause of morbidity and mortality in solid organ transplant recipients and immunocompromised hosts. However, tissue-invasive CMV infection, causing cutaneous or subcutaneous diseases, has been rarely reported in the literature, and proper diagnosis can be easily delayed due to the rarity. Here, we report a rare case of a 45-year-old male renal transplant recipient, presenting with subcutaneous nodules. The nodules were initially suspected as a post-transplant lymphoproliferative disorder (PTLD) on CT scan. However, biopsy later indicated a CMV infection. Based on the present findings, clinicians and radiologists are suggested to consider CMV infection as a differential diagnosis of subcutaneous nodular lesions in solid organ transplant recipients.

scholarly journals Heart transplant recipient survivor from COVID-19: The first case of Turkey

2020 ◽  
Vol 28 (4) ◽  
pp. 674-679
Author(s):  
Güle Çınar
Keyword(s):  
Transplant Recipient ◽  
Heart Transplant ◽  
Organ Transplant ◽  
Heart Transplant Recipient ◽  
Solid Organ Transplant ◽  
Primary Concern ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

Any highly infectious and rapidly spreading disease is a primary concern for immunocompromised solid organ transplant recipients. The number of data about the spectrum of clinical illness, the treatment modalities, and the outcomes of COVID-19 in this vulnerable population is scant and still remains empirical. Herein, we report the first COVID-19 case of a heart transplant recipient in Turkey who presented with fever, postnasal discharge, and myalgias for two days. The possibility of lung involvement was ruled out by thoracic computed tomography. Despite stable vital signs, we reduced the intensity of immunosuppressive therapy and maintained home self-isolation promptly. We also commenced a five-day course of hydroxychloroquine 200 mg q12h initially. After confirmation of real-time reverse-transcriptase-polymerase-chain-reaction testing of the nasopharyngeal swab positive for COVID-19, the patient was hospitalized. After a loading dose of favipiravir 1,600 mg b.i.d., the patient received a five-day course of favipiravir 600 mg q12h. He was discharged with cure after 23 days of hospital isolation and treatment. In conclusion, treatment process can be affected by the daily electrocardiography, hand-held portable echocardiography, myocardial injury markers, and pulse oximeter for self-monitoring in the follow-up of previous heart transplant recipients suffering from COVID-19. The lack of treatment protocols in the solid organ transplant recipients with COVID-19 infection and the controversies about the protective effect of immunosuppression invite a global and update discussion.

scholarly journals Humoral Response to SARS-Cov-2 Vaccination in Liver Transplant Recipients–A Single-Center Experience

Vaccines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 738
Author(s):  
Jassin Rashidi-Alavijeh ◽  
Alexandra Frey ◽  
Moritz Passenberg ◽  
Johannes Korth ◽  
Jaqueline Zmudzinski ◽  
...  
Keyword(s):  
Liver Transplant ◽  
Organ Transplant ◽  
Humoral Response ◽  
Solid Organ Transplant ◽  
Control Group ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Single Center Experience ◽  
Solid Organ Transplant Recipients

Vaccination against SARS-CoV-2 infection is currently approved and shows favorable outcomes, but little known about antibody responses in solid organ transplant recipients, since these patients are known to have an impaired immune response upon vaccination and have not been included in admission studies. We therefore analyzed immunogenicity in 43 liver transplant (LT) recipients in a median of 15 days (IQR, 12–24) after receiving two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 following the standard protocol, and compared these results to a control group consisting of 20 healthcare workers (HCWs). Thirty-four of the 43 (79%) LT recipients developed antibodies, compared to 20 out of 20 (100%) in the control group (p = 0.047). The median SARS-CoV-2 IgG titer was significantly lower in the LT recipients compared to the control group (216 vs. >2080 BAU/mL, p = 0.0001). Age and sex distribution was similar in the LT patients that developed antibodies after vaccination compared to those who did not. Interestingly, the patients who received mycophenolate mofetil exhibited a reduced vaccination response compared to the other LT patients (5 of 11 (45.5%) vs. 29 of 32 (90.6%), p = 0.004). In conclusion, our data reveal lower immunogenicity of SARS-CoV-2 vaccine BNT162b2 in LT patients compared to the control group, but still show superior results compared to other solid organ transplant recipients reported so far.

Sign in / Sign up

Export Citation Format

Share Document